LSV Asset Management acquired a new stake in Thermo Fisher Scientific Inc. (NYSE:TMO) during the second quarter, according to its most recent disclosure with the SEC. The firm acquired 2,113 shares of the company’s stock, valued at approximately $312,000.

Other institutional investors have also added to or reduced their stakes in the company. Signaturefd LLC boosted its position in Thermo Fisher Scientific by 10.6% in the second quarter. Signaturefd LLC now owns 842 shares of the company’s stock valued at $124,000 after buying an additional 81 shares during the period. Tiemann Investment Advisors LLC boosted its position in Thermo Fisher Scientific by 10.2% in the first quarter. Tiemann Investment Advisors LLC now owns 1,625 shares of the company’s stock valued at $230,000 after buying an additional 150 shares during the period. Catawba Capital Management VA boosted its position in Thermo Fisher Scientific by 9.3% in the second quarter. Catawba Capital Management VA now owns 1,642 shares of the company’s stock valued at $243,000 after buying an additional 140 shares during the period. Wedbush Securities Inc. boosted its position in Thermo Fisher Scientific by 4.0% in the second quarter. Wedbush Securities Inc. now owns 1,656 shares of the company’s stock valued at $245,000 after buying an additional 64 shares during the period. Finally, Alpha Windward LLC boosted its position in Thermo Fisher Scientific by 21.3% in the second quarter. Alpha Windward LLC now owns 1,836 shares of the company’s stock valued at $271,000 after buying an additional 322 shares during the period. 87.47% of the stock is currently owned by institutional investors.

Shares of Thermo Fisher Scientific Inc. (NYSE:TMO) traded up 0.03% on Friday, hitting $150.05. The company had a trading volume of 1,985,523 shares. Thermo Fisher Scientific Inc. has a 12-month low of $117.10 and a 12-month high of $160.68. The company has a market capitalization of $59.16 billion, a P/E ratio of 30.02 and a beta of 1.00. The firm has a 50-day moving average price of $153.94 and a 200 day moving average price of $148.48.

Thermo Fisher Scientific (NYSE:TMO) last announced its earnings results on Thursday, July 28th. The company reported $2.03 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $2.01 by $0.02. Thermo Fisher Scientific had a return on equity of 14.70% and a net margin of 11.35%. The business had revenue of $4.54 billion for the quarter, compared to analyst estimates of $4.50 billion. During the same quarter last year, the firm earned $1.84 EPS. Thermo Fisher Scientific’s revenue for the quarter was up 6.2% compared to the same quarter last year. Equities analysts expect that Thermo Fisher Scientific Inc. will post $8.15 EPS for the current year.

The company also recently announced a quarterly dividend, which will be paid on Monday, October 17th. Investors of record on Thursday, September 15th will be given a $0.15 dividend. This represents a $0.60 dividend on an annualized basis and a yield of 0.40%. The ex-dividend date is Tuesday, September 13th. Thermo Fisher Scientific’s dividend payout ratio is presently 12.02%.

Several equities analysts have weighed in on the company. BTIG Research raised Thermo Fisher Scientific from a “neutral” rating to a “buy” rating and set a $180.00 target price on the stock in a research note on Friday, July 22nd. Citigroup Inc. lifted their target price on Thermo Fisher Scientific from $160.00 to $182.00 and gave the company a “buy” rating in a research note on Friday, July 29th. Leerink Swann reaffirmed a “buy” rating on shares of Thermo Fisher Scientific in a research note on Sunday, May 29th. Jefferies Group reaffirmed a “hold” rating on shares of Thermo Fisher Scientific in a research note on Thursday, August 4th. Finally, Zacks Investment Research cut Thermo Fisher Scientific from a “buy” rating to a “hold” rating in a research note on Friday, August 5th. Three research analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the stock. Thermo Fisher Scientific has a consensus rating of “Buy” and an average target price of $159.66.

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 28,797 shares of the firm’s stock in a transaction that occurred on Friday, September 2nd. The stock was sold at an average price of $151.01, for a total value of $4,348,634.97. Following the completion of the transaction, the chief executive officer now directly owns 307,444 shares in the company, valued at $46,427,118.44. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO Marc N. Casper sold 30,000 shares of the firm’s stock in a transaction that occurred on Friday, July 1st. The shares were sold at an average price of $148.85, for a total value of $4,465,500.00. Following the completion of the transaction, the chief executive officer now owns 350,998 shares of the company’s stock, valued at $52,246,052.30. The disclosure for this sale can be found here. 0.52% of the stock is owned by corporate insiders.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc develops, manufactures and sells a range of products. The Company is a provider of analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. The company operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.

5 Day Chart for NYSE:TMO

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO).

Receive News & Ratings for Thermo Fisher Scientific Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.